LOS ANGELES, April 11, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA) investors of a class action representing investors that bought securities between July 30, 2024 and January 8, 2025, inclusive (the "Class Period"). Intellia investors have until April 14, 2025 to file a lead plaintiff motion.Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.Intellia is a genome editing company that focuses on the development of curative therapeutics. According to the complaint, on July ...Full story available on Benzinga.com
Intellia Therapeutics is a Massachusetts-based biotechnology company that researches and develops genome editing therapies to treat genetic and oncological diseases.